TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26433727
Drug: Slow clozapine
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Slow clozapine titration (started at 12.5-50 mg, increased by 25-50 mg/day)
Study: 26433727
Drug: Rapid clozapine
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rapid clozapine titration
Study: 26433727
Drug: Slow clozapine
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Slow clozapine titration
Study: 24673714
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose (SD) of enteric-coated mycophenolate sodium (1440 mg/day)
Study: 24673714
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (LD) of enteric-coated mycophenolate sodium (1080 mg/day)
Study: 24673714
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose (SD) of enteric-coated mycophenolate sodium
Study: 24673714
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (LD) of enteric-coated mycophenolate sodium
Study: 22530305
Drug: Ibandronate (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate (30 mg) with SNAC (1:5 ratio)
Study: 22530305
Drug: Ibandronate (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate (30 mg) with SNAC (1:10 ratio)
Study: 22530305
Drug: Ibandronate (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate (30 mg) with SNAC (1:20 ratio)
Study: 22530305
Drug: Approved oral
Normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Approved oral Ibandronate tablet formulations (150 mg IBN)
Study: 22530305
Drug: Increasing post-dose
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing post-dose fasting duration from 15 to 30 min
Study: 22530305
Drug: IBN/SNAC treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBN/SNAC treatments
Study: 15752384
Drug: Paracetamol 4
Normalized name: Paracetamol 48.2 mg/mL oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 4 g day(-1)
Study: 2258297
Drug: Interferon Alfa‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon Alfa‐2b (Intron A) administered at a low-dose regimen (1 million I.U. s.c. daily for 6 days with a 2-week interval between courses)
Study: 6786074
Drug: Cysteine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cysteine supplementation (77 mg/kg/24 h)
Study: 6786074
Drug: Control intravenous
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control intravenous formulations
Study: 29679529
Drug: Parenteral ω‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral ω‐3 LC‐PUFAs (EPA and DHA)
Study: 29679529
Drug: None of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: None of the parenteral lipid emulsions
Study: 25039675
Drug: Exenatide vs
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide vs Insulin
Study: 19009634
Drug: Azathioprine (AZA)
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine (AZA) 2.0-2.5 mg/kg a day
Study: 19009634
Drug: Budesonide (BUD)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (BUD) 6-9 mg a day
Study: 18812202
Drug: pTHr.HIVA DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: pTHr.HIVA DNA vaccine (0.5 mg or 2 mg) followed by MVA.HIVA (5 x 10^7) at weeks 8 and 12 (early boost) or weeks 20 and 24 (late boost)
Study: 18812202
Drug: pTHr.HIVA DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: pTHr.HIVA DNA vaccine (0.5 mg or 2 mg) followed by MVA.HIVA (5 x 10^7)
Study: 28146560
Drug: Weekly drink
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly drink self-tracking mobile assessment texts (MA)
Study: 26201694
Drug: 0.1 g/kg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 g/kg/h of glucose
Study: 23958074
Drug: 20 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg of oral T3 every 12 hours starting 20 minutes before anesthetic induction, for a total of 4 doses
Study: 19190958
Drug: Fluoxetine (20mg)
Normalized name: fluoxetine 20 MG
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (20mg)
Study: 17141739
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (24 IU Syntocinon)
Study: 8153781
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of ketorolac orally
Study: 8153781
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of morphine intramuscularly
Study: 8153781
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of morphine intramuscularly
Study: 27548886
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg CoQ10 supplementation for 12 weeks
Study: 27548886
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg CoQ10 supplementation for 12 weeks
Study: 14573316
Drug: Hydrocortisone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (100 mg orally)
Study: 8476616
Drug: Morphine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.1 mg/kg added to axillary block solution (AX)
Study: 8476616
Drug: Saline added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline added to axillary block solution with morphine 0.1 mg/kg IV (CT)
Study: 3090830
Drug: High-dose cytosine
Normalized name: cytosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytosine arabinoside (HIDARAC)
Study: 16157900
Drug: Mitoxantrone 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone 12 mg/m2
Study: 16157900
Drug: Mitoxantrone 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone 5 mg/m2
Study: 10953829
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (omeprazole, tetracycline, metronidazole, bismuth subcitrate) for 7 days followed by OCA7 if failure
Study: 10953829
Drug: OCA7 for
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCA7 for 7 days followed by quadruple therapy if failure
Study: 6392353
Drug: Intramuscular levonantradol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular levonantradol 0.5 mg
Study: 6392353
Drug: Intramuscular levonantradol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular levonantradol 1.0 mg
Study: 6392353
Drug: Intramuscular levonantradol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular levonantradol 1.5 mg
Study: 6392353
Drug: Intramuscular levonantradol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular levonantradol 2.0 mg
Study: 31059641
Drug: HTTRx (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTTRx (10 mg)
Study: 31059641
Drug: HTTRx (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTTRx (30 mg)
Study: 31059641
Drug: HTTRx (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTTRx (60 mg)
Study: 31059641
Drug: HTTRx (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTTRx (90 mg)
Study: 31059641
Drug: HTTRx (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTTRx (120 mg)
Study: 28578601
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (single-agent chemotherapy of physician's choice)
Study: 25835109
Drug: 5 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 µg ramosetron
Study: 17129592
Drug: Royal Drug
Normalized name: ROYAL JELLY
DrugBank: Royal jelly (DB14250)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Royal Drug albendazole
Study: 14695734
Drug: Oral amantadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amantadine
Study: 15892278
Drug: Gufusheng capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gufusheng capsule (GFSC) combined with arthrectomy hip synovial membrane excision, femoral head decompression, and muscle-bone flap transplantation
Study: 8598699
Drug: Continued second-line
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued second-line therapy (n = 142)
Study: 1662127
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of 300 mg on the first day and 150 mg for the subsequent 5 days (Group 1)
Study: 1662127
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of 400 mg on the first day and 200 mg for the subsequent 5 days (Group 2)
Study: 6123123
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg cloxazolam
Study: 29645317
Drug: Slow infusion
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow infusion (SI) of low-dose ketamine (0.3 mg/kg)
Study: 29645317
Drug: Intravenous push
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous push (IVP) of low-dose ketamine (0.3 mg/kg)
Study: 24213962
Drug: High-intensity blue
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity blue light therapy (λmax = 465 nm, 84.8 µW/cm(2), 39.5 lux, 1.74 × 10(14) photons/cm(2)/s)
Study: 24213962
Drug: Lower-intensity yellow
Normalized name: yellow OB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-intensity yellow light therapy (λmax = 574 nm, 18.5 µW/cm(2), 68 lux, 1.21 × 10(12) photons/cm(2)/s)
Study: 22947842
Drug: Complete oral
Normalized name: Canker Complete Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete oral prophylaxis (periodontal therapy)
Study: 16291984
Drug: Sildenafil (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (one year treatment)
Study: 11889322
Drug: GIK solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIK solution (30% glucose in water with insulin 50 IU/L, and KCl 40 mM) at 1.5 mL/kg/hr for 24 hrs
Study: 11889322
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline) at 1.5 mL/kg/hr for 24 hrs
Study: 21591581
Drug: G-CSF (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (10 microg/kg body weight) for five consecutive days
Study: 15731121
Drug: Topical tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tacrolimus 0.03%
Study: 19922703
Drug: Topical pimecrolimus
Normalized name: pimecrolimus Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical pimecrolimus
Study: 15731121
Drug: Topical pimecrolimus
Normalized name: pimecrolimus Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical pimecrolimus and tacrolimus
Study: 12018715
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (1 g IV for 3 days in weeks 1 and 2, 2 days in week 3, 1 day in week 4)
Study: 12018715
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (1.5 mg/kg/day for 4 weeks)
Study: 10638398
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg DHEM/2% RAMEB nasal spray
Study: 10638398
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg DHEM/4 mg RAMEB nasal powder
Study: 10638398
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg Diergo nasal spray
Study: 10638398
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg DHEM solution p.o.
Study: 10638398
Drug: i.m. administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. administration of 0.5 mg DHEM
Study: 30672233
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with Betastatin mesylate (12 mg, 3 times a day) and mecobalamin (0.5 mg, 3 times a day)
Study: 30672233
Drug: Simple western
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple western medication (Betastatin mesylate 12 mg, 3 times a day and mecobalamin 0.5 mg, 3 times a day)
Study: 23039913
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy (CBT) group training
Study: 19830574
Drug: Basal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal therapy
Study: 16243716
Drug: Enzyme extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme extract (900 mg) in three divided doses
Study: 16243716
Drug: Enzyme therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme therapy
Study: 11857598
Drug: 5-aminolaevulinic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-aminolaevulinic acid (ALA) 60 mg/kg BW, oral, 6-8 hours prior to PDT
Study: 11857598
Drug: Photosan 2
Normalized name: Chitosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photosan 2 mg/kg BW, i.v., 48 hours before PDT
Study: 8520561
Drug: Chemotherapy (ChT)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (ChT) plus radiotherapy (RT)
Study: 8520561
Drug: Chemotherapy (ChT)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (ChT) alone
Study: 8520561
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who achieved complete response (CR) after treatment
Study: 2215254
Drug: Aspartame-sweetened beverage
Normalized name: Aspartame
DrugBank: Aspartame (DB00168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame-sweetened beverage (600 mg APM per serving)
Study: 27473440
Drug: Structured lifestyle
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured lifestyle intervention group (IG) with monthly group training sessions and regular telephone contacts.
Study: 25162191
Drug: Brief cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief cognitive behavioral therapy (3 weeks, 6 sessions)
Study: 17482623
Drug: Pioglitazone 30
Normalized name: pioglitazone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 30 mg daily for 4 weeks, increasing to 45 mg for 12 weeks
Study: 16130888
Drug: Taking OTC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taking OTC medication
Study: 16130888
Drug: Having a
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Having a family doctor and number of OTC medicines on hand
Study: 16130888
Drug: Three or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three or more kinds of OTC medicine
Study: 7272675
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg i.v. preoperatively
Study: 7272675
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg i.v. preoperatively
Study: 7272675
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg i.v. postoperatively
Study: 7272675
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg i.v. preoperatively and 200 mg i.v. daily for 3 days postoperatively
Study: 24445723
Drug: Azilsartan medoxomil
Normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan medoxomil 40 mg + amlodipine 5 mg
Study: 24445723
Drug: Azilsartan medoxomil
Normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan medoxomil 80 mg + amlodipine 5 mg
Study: 24445723
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + amlodipine 5 mg
Study: 15781511
Drug: IV fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV fentanyl 50 microg/mL (100 microg)
Study: 15781511
Drug: IV lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV lidocaine 2% (40 mg)
Study: 10759820
Drug: Hydroquinone 4%
Normalized name: HYDROQUINONE 4% CREAM
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroquinone 4% cream with 2% glycolic acid applied twice daily for 12 weeks
Study: 10759820
Drug: Hydroquinone 4%
Normalized name: HYDROQUINONE 4% CREAM
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroquinone 4% cream with 2% glycolic acid plus salicylic acid peels every 3 weeks
Study: 1355645
Drug: Inhaled salmeterol
Normalized name: salmeterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol xinafoate (50 micrograms)
Study: 6389973
Drug: Prophylactic antilymphocyte
Normalized name: antilymphocyte immunoglobulin
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antilymphocyte globulin (ALG) treatment for 21 days
Study: 6389973
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no ALG treatment)
Study: 29589153
Drug: Dapagliflozin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (5 or 10 mg, once daily orally)
Study: 29589153
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (anti-diabetic drugs other than SGLT-2 inhibitors)
Study: 16784898
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg daily oral DHEA replacement for one year
Study: 15725968
Drug: Atomoxetine (fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (fixed dosing: 0.5, 1.2, or 1.8 mg/kg/day, b.i.d.)
Study: 15725968
Drug: Atomoxetine (1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (1.8 mg/kg/day)
Study: 2675432
Drug: Morphine and
Normalized name: morphine and antispasmodics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine and Paracetamol
Study: 26374825
Drug: Alirocumab 150
Normalized name: alirocumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 150 mg administered subcutaneously every 2 weeks
Study: 12929752
Drug: Intraoperative photodynamic
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative photodynamic therapy (PDT) using Foscan at a dose of 0.1 mg/kg 6 days before surgery and 652 nm red light at a dose of 10 J/cm2
Study: 11044498
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment with medroxyprogesterone acetate
Study: 11044498
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment with danazol
Study: 11044498
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment with nafarelin
Study: 11044498
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy after surgical treatment
Study: 8970686
Drug: 15 mg/day
Normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/day oxandrolone
Study: 8970686
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day oxandrolone
Study: 1483989
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet twice daily
Study: 3883235
Drug: Clonidine (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.125 to 0.3 mg/d)
Study: 28546367
Drug: Intensive PD
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive PD dosage (> 30 L per day)
Study: 28546367
Drug: Minimal standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal standard PD dosage (< 20 L per day)
Study: 19843056
Drug: Intravenous alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alcohol clamping to maintain a pseudo-steady-state BrAC of 0.6 g l(‐1)
Study: 17854250
Drug: venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: venlafaxine ER (75 to 300 mg/day)
Study: 9544380
Drug: Bismuth subcitrate
Normalized name: BISMUTH SUBCITRATE
DrugBank: Bismuth subcitrate potassium (DB09275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth subcitrate one tablet qid, tetracycline 500 mg qid and metronidazole 400 mg tds (BTM)
Study: 9544380
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg bd, amoxycillin 500 mg qid and metronidazole 400 mg tds (LAM)
Study: 2462264
Drug: 3 times/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 times/week at 2 Gy/day twice a day at a minimum interval of 6 h for a total of 20 Gy/10 fractions (Group III)
Study: 28651151
Drug: IVR with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVR with weekly schedule
Study: 28651151
Drug: IVR with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVR with daily schedule
Study: 28651151
Drug: SMS with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMS with weekly schedule
Study: 28651151
Drug: SMS with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMS with daily schedule
Study: 28651151
Drug: IVR (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVR (daily and weekly)
Study: 28651151
Drug: SMS (weekly)
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMS (weekly)
Study: 23759267
Drug: Beverage containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beverage containing 11% pea protein hydrolysate and 89% carbohydrates (79% maltodextrin and 21% sucrose), 400 mL the night before and 200 mL 3 h before surgery
Study: 11106122
Drug: Separate tablets
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate tablets of eniluracil (20 mg) and 5-FU (2 mg)
Study: 11106122
Drug: Combined eniluracil/5-FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined eniluracil/5-FU tablets (10/1 mg)
Study: 11106122
Drug: Combined eniluracil/5-FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined eniluracil/5-FU tablets (2.5/0.25 mg)